Engelhard Arzneimittel GmbH & Co.KG

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Oct 3, 2025FDAXeloda — XELODA

Dec 14, 2022FDAXeloda — XELODA

1 more events

Jan 8, 2021TrialSinolpan® Pharmacy Non-interventional Study - Quality of Live

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

Valcyte2 patentsDec 11, 2027

Regulatory

Regulatory Timeline

20171 event

FDAJun 22

Valcyte — VALCYTE

Application NDA022257

20182 events

FDAAug 2

Valcyte — VALCYTE

Application NDA022257

FDAAug 2

Valcyte — VALCYTE

Application NDA021304

20191 event

FDAFeb 22

Xeloda — XELODA

Application NDA020896

20204 events

FDANov 24

Valcyte — VALCYTE

Application NDA022257

FDANov 24

Valcyte — VALCYTE

Application NDA021304

FDAOct 21

Valcyte — VALCYTE

Application NDA022257

FDAOct 21

Valcyte — VALCYTE

Application NDA021304

20213 events

FDADec 23

Valcyte — VALCYTE

Application NDA021304

FDADec 23

Valcyte — VALCYTE

Application NDA022257

FDAMay 19

Xeloda — XELODA

Application NDA020896

20228 events

FDADec 14

Xeloda — XELODA

Application NDA020896

FDADec 14

Xeloda — XELODA

Application NDA020896

FDADec 14

Xeloda — XELODA

Application NDA020896

FDADec 14

Xeloda — XELODA

Application NDA020896

FDADec 14

Xeloda — XELODA

Application NDA020896

FDADec 14

Xeloda — XELODA

Application NDA020896

FDADec 14

Xeloda — XELODA

Application NDA020896

FDADec 14

Xeloda — XELODA

Application NDA020896

20251 event

FDAOct 3

Xeloda — XELODA

Application NDA020896

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)